Androgen replacement therapy

被引:27
作者
Wang, C
Swerdloff, RS
机构
[1] Harbor UCLA Med Ctr, Div Endocrinol, Clin Study Ctr, Torrance, CA 90509 USA
[2] Harbor UCLA Med Ctr, Dept Med, Torrance, CA 90509 USA
关键词
ageing men; pharmacokinetics; risks and benefits; testosterone;
D O I
10.3109/07853899708999363
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Androgen therapy has been primarily used for replacement therapy in symptomatic hypogonadal men. Other indications under clinical investigation include androgen replacement therapy for older men with age-associated decline in serum testosterone levels, muscle-wasting disease, male contraception and as adjunctive therapy to oestrogen (and progesterone) hormone replacement for postmenopausal women. Recent scientific and pharmaceutical interests led to development of new long-acting injectables, transdermal delivery systems and sublingual preparations. The benefits of androgen replacement must be weighed against the potential risks when androgens are used in conditions other than male hypogonadism. In the future, designer androgens with specific beneficial effect on sexual function, mood, bone and muscle mass but with attenuated effects on serum lipid profiles and the prostate gland may be developed.
引用
收藏
页码:365 / 370
页数:6
相关论文
共 30 条
  • [1] Drug therapy - Androgens in men - Uses and abuses
    Bagatell, CJ
    Bremner, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) : 707 - 714
  • [2] METABOLIC AND BEHAVIORAL-EFFECTS OF HIGH-DOSE, EXOGENOUS TESTOSTERONE IN HEALTHY-MEN
    BAGATELL, CJ
    HEIMAN, JR
    MATSUMOTO, AM
    RIVIER, JE
    BREMNER, WJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (02) : 561 - 567
  • [3] ANDROGENS - RISKS AND BENEFITS
    BARDIN, CW
    SWERDLOFF, RS
    SANTEN, RJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (01) : 4 - 7
  • [5] BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
  • [6] TESTOSTERONE BUCICLATE (20 AET-1) IN HYPOGONADAL MEN - PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NEW LONG-ACTING ANDROGEN ESTER
    BEHRE, HM
    NIESCHLAG, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (05) : 1204 - 1210
  • [7] A BIODEGRADABLE TESTOSTERONE MICROCAPSULE FORMULATION PROVIDES UNIFORM EUGONADAL LEVELS OF TESTOSTERONE FOR 10-11 WEEKS IN HYPOGONADAL MEN
    BHASIN, S
    SWERDLOFF, RS
    STEINER, B
    PETERSON, MA
    MERIDORES, T
    GALMIRINI, M
    PANDIAN, MR
    GOLDBERG, R
    BERMAN, N
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (01) : 75 - 83
  • [8] The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
    Bhasin, S
    Storer, TW
    Berman, N
    Callegari, C
    Clevenger, B
    Phillips, J
    Bunnell, TJ
    Tricker, R
    Shirazi, A
    Casaburi, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) : 1 - 7
  • [9] Testosterone replacement increases fat-free mass and muscle size in hypogonadal men
    Bhasin, S
    Storer, TW
    Berman, N
    Yarasheski, KE
    Clevenger, B
    Phillips, J
    Lee, WP
    Bunnell, TJ
    Casaburi, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 407 - 413
  • [10] BHASIN S, 1996, PHARM BIOL CLIN APPL